Actively Recruiting
Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control
Led by Shanghai 6th People's Hospital · Updated on 2024-11-29
150
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.
CONDITIONS
Official Title
Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years old
- Diagnosed with type 2 diabetes and admitted to the Department of Endocrinology and Metabolism
- HbA1c level between 8% and 12% in the last month
- Receiving insulin therapy within one month of planned hospital discharge
- Self-monitoring blood glucose less than 4 times per week and no use of real-time continuous glucose monitoring in the 3 months before hospitalization
- Willing and able to provide written informed consent and comply with study requirements
You will not qualify if you...
- Receiving oral steroid hormone therapy
- Having acute diabetes complications such as diabetic ketoacidosis, hyperglycemia with hyperosmolality, or lactic acidosis
- Severe liver disease with liver enzymes more than three times the upper normal limit
- Severe kidney injury or end-stage renal disease with eGFR less than 30 mL/min/1.73 m2
- Unable to tolerate tape adhesive around the sensor area or having allergies or serious skin diseases at the sensor site
- Mental conditions preventing understanding of the study's nature and consequences
- Pregnant, breastfeeding, or women of childbearing age unwilling to use contraception during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai 6th People's Hospital
Shanghai, Shanghai Municipality, China, 200233
Actively Recruiting
Research Team
S
Shiyun Wang, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here